Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics

Authors


Reinhold Kilian, Universität Ulm, Abteilung Psychiatrie II, BKH Günzburg, Ludwig-Heilmeyer-Str. 2, D-89312 Günzburg, Germany.
E-mail: reinhold.kilian@bkh-guenzburg.de

Abstract

Objective:  Effects of first in comparison with second-generation antipsychotics on the subjective quality of life (QoL) of patients with schizophrenia under routine treatment conditions were examined.

Method:  In a prospective naturalistic trial the QoL, social, clinical, and treatment-related characteristics and type of antipsychotic medication of 307 patients with schizophrenia (ICD-10 F 20) were assessed five times with 6-month intervals over 2.5 years. Longitudinal and cross-sectional effects of antipsychotic medication were assessed by hierarchical regression models. Selection bias was controlled by propensity scores.

Results:  While positive effects of first-generation antipsychotics on subjective QoL in comparison with no antipsychotic treatment were found, second-generation antipsychotics caused no better QoL than first-generation antipsychotics.

Conclusion:  The hypothesis that second-generation in comparison with first-generation antipsychotics have a better effect on the improvement of subjective QoL of people with schizophrenia in routine out-patient treatment was not supported.

Ancillary